Marc Gregoire

Summary

Country: France

Publications

  1. ncbi [Immunotherapy and malignant mesothelioma: clinical perspectives]
    Marc Gregoire
    INSERM, Unite 601, Institut de Biologie, 9 quai Moncousu, 44093 Nantes Cedex
    Bull Cancer 94:23-31. 2007
  2. ncbi What's the place of immunotherapy in malignant mesothelioma treatments?
    Marc Gregoire
    INSERM, U892, Research Center in Oncology Nantes Angers, France
    Cell Adh Migr 4:153-61. 2010
  3. ncbi Dendritic cell preparation for immunotherapeutic interventions
    Thomas Simon
    INSERM U892, Institut de Biologie, 9 quai Moncousu, 44093 Nantes Cedex 01, France
    Immunotherapy 1:289-302. 2009
  4. ncbi New perspectives in cancer virotherapy: bringing the immune system into play
    Nicolas Boisgerault
    INSERM, U892, CRCNA, IRTUN, Nantes, France
    Immunotherapy 2:185-99. 2010
  5. ncbi Opposite role of Bax and BCL-2 in the anti-tumoral responses of the immune system
    Gwenola Bougras
    UMR 601 INSERM UN, Equipe 2, 9 quai Moncousu 44035 Nantes, France
    BMC Cancer 4:54. 2004
  6. ncbi Vaccination with epigenetically treated mesothelioma cells induces immunisation and blocks tumour growth
    Flora Guillot
    INSERM, U892, Centre de Recherche en Cancérologie Nantes Angers, Institut de Recherche Therapeutique, Nantes, France
    Vaccine 29:5534-43. 2011
  7. ncbi Yin Yang of immunoregulation in organ transplantation and cancer
    Yves Delneste
    INSERM, U892, Centre de Recherche sur le Cancer Nantes Angers, F 49933 Angers, France
    Immunotherapy 3:1-3. 2011
  8. ncbi Measles virus induces oncolysis of mesothelioma cells and allows dendritic cells to cross-prime tumor-specific CD8 response
    Anne Gauvrit
    INSERM, U601, Cancerology Research Department, Nantes, France
    Cancer Res 68:4882-92. 2008
  9. ncbi Efficient monocyte-derived dendritic cell generation in patients with acute myeloid leukemia after chemotherapy treatment: application to active immunotherapy
    Pierre Joseph Royer
    INSERM, U601, Nantes, France Université de NANTES, Faculte de Medecine, Centre de Recherche en Oncologie, Nantes, France
    Exp Hematol 36:329-39. 2008
  10. ncbi A 5-aza-2'-deoxycytidine/valproate combination induces cytotoxic T-cell response against mesothelioma
    S Leclercq
    INSERM, U892, Institut de Recherche Therapeutique, Universite de Nantes, Nantes, France
    Eur Respir J 38:1105-16. 2011

Collaborators

  • Frederic Tangy
  • Patrice Chevallier
  • Yves Delneste
  • Jean Luc Harousseau
  • Gwenola Bougras
  • Nicolas Boisgerault
  • Thomas Simon
  • Flora Guillot
  • S Leclercq
  • Jean Francois Fonteneau
  • Pierre Joseph Royer
  • Anne Gauvrit
  • Dorian McIlroy
  • Daniel Pouliquen
  • Myriam Robard
  • F Guillot
  • M Padieu
  • F Gueugnon
  • D Pouliquen
  • A Rogel
  • Benoît Boutin
  • Christophe Blanquart
  • J F Fonteneau
  • B Boutin
  • C Blanquart
  • Lucie Leveque
  • Carole Sapede-Peroz
  • Pierre-Joseph Royer
  • Nadine Juge-Morineau
  • Frederic Ebstein
  • Samantha Brandler
  • Severine Tanguy-Royer

Detail Information

Publications13

  1. ncbi [Immunotherapy and malignant mesothelioma: clinical perspectives]
    Marc Gregoire
    INSERM, Unite 601, Institut de Biologie, 9 quai Moncousu, 44093 Nantes Cedex
    Bull Cancer 94:23-31. 2007
    ..This article will review past and recent developments of such a clinical strategy...
  2. ncbi What's the place of immunotherapy in malignant mesothelioma treatments?
    Marc Gregoire
    INSERM, U892, Research Center in Oncology Nantes Angers, France
    Cell Adh Migr 4:153-61. 2010
    ..This article reviews past and recent developments of the clinical strategies that concern immunotherapy of mesothelioma...
  3. ncbi Dendritic cell preparation for immunotherapeutic interventions
    Thomas Simon
    INSERM U892, Institut de Biologie, 9 quai Moncousu, 44093 Nantes Cedex 01, France
    Immunotherapy 1:289-302. 2009
    ..Finally, we discuss the immunological and clinical outcomes in treated patients, with emphasis on the strategies that could be used to improve DC-based vaccination...
  4. ncbi New perspectives in cancer virotherapy: bringing the immune system into play
    Nicolas Boisgerault
    INSERM, U892, CRCNA, IRTUN, Nantes, France
    Immunotherapy 2:185-99. 2010
    ..These findings offer an exciting outlook for the future of cancer virotherapy...
  5. ncbi Opposite role of Bax and BCL-2 in the anti-tumoral responses of the immune system
    Gwenola Bougras
    UMR 601 INSERM UN, Equipe 2, 9 quai Moncousu 44035 Nantes, France
    BMC Cancer 4:54. 2004
    ..The relative role of anti apoptotic (i.e. Bcl-2) or pro-apoptotic (e.g. Bax) proteins in tumor progression is still not completely understood...
  6. ncbi Vaccination with epigenetically treated mesothelioma cells induces immunisation and blocks tumour growth
    Flora Guillot
    INSERM, U892, Centre de Recherche en Cancérologie Nantes Angers, Institut de Recherche Therapeutique, Nantes, France
    Vaccine 29:5534-43. 2011
    ..Our data demonstrate that epigenetic drugs, such as SAHA, can stimulate tumour immunogenicity and improve the recognition of aggressive MM cells by the immune system in vivo...
  7. ncbi Yin Yang of immunoregulation in organ transplantation and cancer
    Yves Delneste
    INSERM, U892, Centre de Recherche sur le Cancer Nantes Angers, F 49933 Angers, France
    Immunotherapy 3:1-3. 2011
    ....
  8. ncbi Measles virus induces oncolysis of mesothelioma cells and allows dendritic cells to cross-prime tumor-specific CD8 response
    Anne Gauvrit
    INSERM, U601, Cancerology Research Department, Nantes, France
    Cancer Res 68:4882-92. 2008
    ..Altogether, these data strongly support the potential of oncolytic MV as an efficient therapeutic agent for mesothelioma cancer...
  9. ncbi Efficient monocyte-derived dendritic cell generation in patients with acute myeloid leukemia after chemotherapy treatment: application to active immunotherapy
    Pierre Joseph Royer
    INSERM, U601, Nantes, France Université de NANTES, Faculte de Medecine, Centre de Recherche en Oncologie, Nantes, France
    Exp Hematol 36:329-39. 2008
    ..The aim of our study was to assess, for vaccine preparation, generation of monocyte-derived DCs in AML patients after CT...
  10. ncbi A 5-aza-2'-deoxycytidine/valproate combination induces cytotoxic T-cell response against mesothelioma
    S Leclercq
    INSERM, U892, Institut de Recherche Therapeutique, Universite de Nantes, Nantes, France
    Eur Respir J 38:1105-16. 2011
    ..This property could be exploited in clinical investigations to develop MPM treatments combining chemotherapeutic and immunotherapeutic approaches...
  11. ncbi Optimizing dendritic cell-based anticancer immunotherapy: maturation state does have clinical impact
    Dorian McIlroy
    INSERM U419, Institut de Biologie, 9 quai Moncousu, 44000 Nantes, France
    Cancer Immunol Immunother 52:583-91. 2003
    ..However, TNF-alpha is not the only molecule capable of inducing DC maturation, and strategies for improving clinical responses by optimizing DC maturation are discussed...